Picture of ResMed logo

RMD — ResMed News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Resmed Inc expected to post earnings of $2.04 a share - Earnings Preview

* Resmed Inc  RMD.N   RMD  is expected to show a rise in
quarterly
revenue when it reports  results on October 24 for the period
ending September 30 2024
    * The San Diego California-based  company is expected to
report a
7.1% increase in revenue to $1.18 billion from $1.1 billion a
year ago, according to the mean estimate from 12 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Resmed Inc is for
earnings of
$2.07 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months. ​
    * Wall Street's median 12-month price target for Resmed Inc
is
236.33​, below​ its last closing price of $239.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  2.05        2.07       2.08      Beat    0.6
 Jan. 1 2024   1.92        1.91       2.13      Beat    11.3
 Dec. 31 2023  1.80        1.80       1.88      Beat    4.7​
 Sep. 30 2023  1.61        1.62       1.64      Beat    1.4
 ​​Jun.        1.69        1.69       1.60      Missed  -5.4
 30 2023                                                
 Mar. 31 2023  1.59        1.59       1.68      Beat    5.9​
 Dec. 31 2022  1.63        1.62       1.66      Beat    2.6
 Jan. 1 0001   1.52        1.52       1.51      Missed  -0.4
 This summary was machine generated October 23 at 03:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on ResMed

See all news